PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

Cancer-associated venous thromboembolism

AA Khorana, N Mackman, A Falanga… - Nature reviews Disease …, 2022 - nature.com
Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Complex heatmap visualization

Z Gu - Imeta, 2022 - Wiley Online Library
Heatmap is a widely used statistical visualization method on matrix‐like data to reveal
similar patterns shared by subsets of rows and columns. In the R programming language …

Emerging therapies for glioblastoma: current state and future directions

L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Federated learning enables big data for rare cancer boundary detection

S Pati, U Baid, B Edwards, M Sheller, SH Wang… - Nature …, 2022 - nature.com
Although machine learning (ML) has shown promise across disciplines, out-of-sample
generalizability is concerning. This is currently addressed by sharing multi-site data, but …

Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target

N Abdelfattah, P Kumar, C Wang, JS Leu… - Nature …, 2022 - nature.com
A major rate-limiting step in developing more effective immunotherapies for GBM is our
inadequate understanding of the cellular complexity and the molecular heterogeneity of …

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

PY Wen, A Stein, M van den Bent, J De Greve… - The lancet …, 2022 - thelancet.com
Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

IK Mellinghoff, M Lu, PY Wen, JW Taylor, EA Maher… - Nature medicine, 2023 - nature.com
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

W Wu, JL Klockow, M Zhang, F Lafortune… - Pharmacological …, 2021 - Elsevier
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Glioma progression is shaped by genetic evolution and microenvironment interactions

FS Varn, KC Johnson, J Martinek, JT Huse… - Cell, 2022 - cell.com
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …